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OBJECTIVES: Irritable bowel syndrome (IBS) is a chronic and
symptomatic gastrointestinal disorder characterized by abdomi-
nal pain/discomfort, bloating and altered bowel habit.
Tegaserod, a 5-HT4 receptor antagonist, is effective, safe, and
well tolerated in the treatment of patients with irritable bowel
syndrome (IBS) with constipation. Due to increasing pressure on
health care budgets, it has become important to investigate not
only the clinical safety and efﬁcacy of new treatments, but also
their cost-effectiveness (C/E). The aim of this study was to assess,
from a payor perspective, whether tegaserod would be C/E in the
treatment of IBS patients, excluding those with IBS with diar-
rhea. METHODS: Female and male subjects were randomized
to receive tegaserod 6mg b.i.d or placebo for 12 weeks. Patients
(247 tegaserod; 238 placebo) ﬁlled out the EuroQol (EQ-5D) at
baseline, Week 4, and Week 12. A 12-week economic study was
undertaken to assess the incremental cost-effectiveness (ICER) of
tegaserod. Costs and beneﬁts were bootstrapped to obtain 95%
conﬁdence intervals of the ICER. C/E acceptability curves were
calculated using a range of daily costs of tegaserod, and the prob-
ability of treatment being C/E was assessed at threshold willing-
ness to pay of 50,000€ per quality-adjusted life-year (QALY).
RESULTS: The utility gained between tegaserod and placebo cal-
culated as the difference between the areas under the curve was
0.0077 over 12 weeks in favor of tegaserod. Assuming a daily
tegaserod cost of 2€, 3€ and 4€ and 0€ for placebo, the median
ICER of tegaserod ranged between 19,000€ and 38,000€ per
QALY gained, with the probability of being C/E at threshold of
50,000€ per QALY ranging from 90% to 69%. CONCLU-
SIONS: This study established from a randomized controlled
clinical trial that tegaserod is C/E in the treatment of patients
with non-diarrhea IBS.
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OBJECTIVES: UK guidelines for managing acute mania call for
initiation of treatment with mood stabilizer or antipsychotic
monotherapy. Although atypical antipsychotics are better toler-
ated and may provide more rapid symptom resolution than con-
ventional antipsychotics, conventional antipsychotics are widely
used in practice due to lower acquisition costs. The objective of
this study was to assess the cost-effectiveness of atypical antipsy-
chotics in acute mania. METHODS: We developed a state-tran-
sition Markov model to estimate the cost-effectiveness of
antipsychotic monotherapy in patients hospitalized for a new
episode of acute mania. A hypothetical cohort of 1000 patients
was assumed to receive initial therapy with: haloperidol 15
mg/day, olanzapine 15mg/day, or risperidone 4mg/day. Over
subsequent 3-week cycles, patients may remain manic, become
depressed, die from suicide or other causes, or stabilize. The
model tracks patients’ state transitions over 24 weeks and tabu-
lates cumulative lifetime costs. Transition probabilities and cost
estimates were derived from published literature. The NHS per-
spective was applied; therefore only direct medical costs (for
drugs, hospitalization, etc.) were considered. Expected costs,
expected number of treatment responders, and incremental cost
per responder were estimated; response was deﬁned as stabiliza-
tion within the ﬁrst 3-week treatment cycle. The model’s robust-
ness to base-case assumptions was assessed using multivariate
sensitivity analysis. RESULTS: Risperidone monotherapy was
the least costly (£17,260,500) and olanzapine monotherapy 
the most costly (£17,555,300) treatment strategy. Consistent
with drug efﬁcacies reported in the clinical trials, risperidone
monotherapy provided the most responders per 1000 patients
(537) and haloperidol monotherapy the fewest (460). In base-
case analyses, risperidone dominated both haloperidol and olan-
zapine by being both less costly and more effective; however, this
outcome was sensitive to assumptions regarding drug efﬁcacy.
CONCLUSIONS: Based on current evidence, risperidone
monotherapy dominates both olanzapine and haloperidol
monotherapy by being both less costly and more effective in the
treatment of acute mania.
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OBJECTIVES: To project the cumulative incidence (CI) of end-
stage renal disease (ESRD), life expectancy (LE) and costs of
treating patients with diabetes, hypertension, and microalbu-
minuria with either standard hypertension treatment alone
(control) or standard hypertension treatment plus irbesartan 300
mg daily in Spanish, Swedish, and Swiss settings. METHODS:
A peer-reviewed, published Markov/Monte Carlo model simu-
lated progression from microalbuminuria to nephropathy, dou-
bling of serum creatinine, ESRD, and all-cause mortality in
patients with hypertension, type 2 diabetes and microalbumin-
uria was adapted to Spanish, Swedish, and Swiss settings using
country-speciﬁc costs and ESRD outcomes data. CI of ESRD,
costs and LE were projected for a hypothetical cohort of 1000
subjects. Future costs and LE were discounted at recommended
country-speciﬁc rates. A 25-year time horizon and third party
payer perspective were used. Sensitivity analysis was performed.
RESULTS: When compared to standard blood pressure control,
irbesartan was projected to reduce the CI of ESRD from (mean
± standard deviation) 24 ± 1% to 9 ± 2%, save 11,082€ ± 2996€,
SEK 124,018 ± 31,000 and CHF 18,057 ± 4646 in the Spanish,
Swedish and Swiss settings respectively, and add 1.40 ± 0.27,
1.49 ± 0.27 and 1.41 ± 0.28 life years per treated patient in the
Spanish, Swedish and Swiss settings respectively. Costs of dialy-
sis and renal transplantation were the major cost drivers. The
advantages associated with irbesartan over standard care was
robust under a wide range of plausible assumptions. CONCLU-
SIONS: Treating patients with hypertension, microalbuminuria
and type 2 diabetes with irbesartan was projected to reduce the
incidence of ESRD, extend life and reduce costs in all 3 coun-
tries analysed.
